Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says

MT Newswires Live04-14

Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.

Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.

A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.

The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.

Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.

Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.

RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.

Price: 152.47, Change: +1.33, Percent Change: +0.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627440374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 23:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627440374","market":"sg","top_or_hot":-1,"title":"Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/INSM\">Insmed</a> (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.</p><p>Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.</p><p>A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.</p><p>The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.</p><p>Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.</p><p>Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.</p><p>RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.</p><p>Price: 152.47, Change: +1.33, Percent Change: +0.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-14 23:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/INSM\">Insmed</a> (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.</p><p>Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.</p><p>A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.</p><p>The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.</p><p>Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.</p><p>Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.</p><p>RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.</p><p>Price: 152.47, Change: +1.33, Percent Change: +0.88</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2627440374","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627440374","pubTimestamp":1776179700,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Insmed  is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.Price: 152.47, Change: +1","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed","BK4139":"生物科技","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4207":"综合性银行","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC"},"translate_title":"加拿大皇家银行资本市场表示，Insmed看到了医生对Brinsupri的良好反馈","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.Price: 152.47, Change: +1.33, Percent Change: +0.88","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627440374","isCrawlerRequest":true}